Where does Concert Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Concert Pharmaceuticals, Inc. ranks #4,759 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Concert Pharmaceuticals, Inc. hold?

Concert Pharmaceuticals, Inc. holds 73 US utility patents granted between 2015 and 2025, spanning 12 technology areas.

What is Concert Pharmaceuticals, Inc.'s Innovation Score?

Concert Pharmaceuticals, Inc. has an Innovation Score of 38.1 out of 100 (top 42% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Concert Pharmaceuticals, Inc. focus on?

Concert Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 64 patents, ranking #265 of 6,058 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Concert Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Concert Pharmaceuticals, Inc.'s recent grant velocity is -84% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Concert Pharmaceuticals, Inc.'s patents?

Concert Pharmaceuticals, Inc.'s patents average 16.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Concert Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Concert Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 73 granted patents across 12 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Concert ranks #4,759 of 49,997 tracked US assignees by granted-patent volume, with 73 patents across 12 technology areas.

#4,759
of 49,997 US assignees by volume: Top 42%
by Innovation Score (38.1/100): 16.7
avg claims per patent: -84%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4759 · US Corporation #4,759 · 73 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 73 grants
TOP-DECILE #4,759/49,997
PHOTO-FINISH Canon Denshi
CPC-FOCUS A61P · 12 areas
INNOV-THIN 38.1/100
CLAIMS-RICH 16.7 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -84% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Canon Denshi Kabushiki Kaisha (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Concert’s 38.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.9 pts (39%) Velocity 1.0 pts (3%) Breadth 12.2 pts (32%) Claim depth 10.0 pts (26%)

Qualcomm Incorporated · highest

85
Rhizen Pharmaceuticals · near

38
Concert Pharmaceutic… · this assignee

38
D R Systems · near

38
SDL · near

38
Shoot-A-Way · near

38
3D Lighting… · lowest

7

What this shows Concert's Innovation Score is 38.1/100 (top 42% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Concert?

Each dot is one of Concert’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Concert’s own 16.7 claims/patent is at or below the 18.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Concert vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Concert's grants concentrate

Concert Pharmaceuticals, Inc. is a focused PatentsView assignee: 12 CPC subclasses with 87.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (18 grants) versus a trough of 1 in 2021. By volume, Concert sits between Canon Denshi Kabushiki Kaisha and Dexterity, Inc..

Concert's three-year grant acceleration

Concert Pharmaceuticals, Inc. shows 2 grants in 2022–2024 against only 14 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Canon Denshi

73
Causam Energy

73
Caterpillar Globa…

73
Clearmotion

73
Cook Biotech Inco…

73
Copeland

73
Diamond Innovatio…

73
Dexterity

73
Concert Pharmaceu… ◀

73

What this shows Concert holds 73 patents at rank #4,759, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Concert

By rank, the assignees closest to #4,759 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Concert's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Concert, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Concert ranks #265 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (38 here).

D.R. Systems, Inc. 38 SDL Inc. 38 Shoot-A-Way, Inc. 38 Rhizen Pharmaceuticals AG 38

Similar claim depth

Nearest assignees by average claims per patent (16.7 here).

Magnecomp Corporation 16.7 avg Statoil Petroleum AS 16.7 avg LTS Lohmann Therapie-Systeme AG 16.7 avg GIESECKE+DEVRIENT Currency Technology GMBH 16.7 avg

Concert's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 42% higher than 58% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Concert Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	17	23.3%
2016	18	24.7%
2017	12	16.4%
2018	9	12.3%
2019	6	8.2%
2020	7	9.6%
2021	1	1.4%
2022	2	2.7%
2025partial year	1	1.4%

Which technologies does Concert Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 64

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 57

C07D - Heterocyclic Compounds 56

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 49

C07C - Acyclic OR Carbocyclic Compounds 15

Y02A - Technologies FOR Adaptation TO Climate Change 13

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 2

C12Y - Enzymes 1

C09K - Materials FOR Miscellaneous Applications, NOT Provided FOR Elsewhere 1

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Concert Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Concert Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #4,759 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Concert Pharmaceuticals, Inc. against Canon Denshi Kabushiki Kaisha, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.